（原标题：000908将被实施退市风险警示！宇树科技完成第一期上市辅导工作，多只概念股获资金关 注） 宇树科技完成第一期上市辅导工作。 ST景峰(000908)昨日晚间发布公告称，2025年10月21日，公司收到常德中院送达的《民事裁定书》及 《决定书》，常德中院裁定受理债权人对公司的重整申请。 根据《深圳证券交易所股票上市规则》的相关规定，公司股票交易将于2025年10月23日被实施退市风险 警示，股票简称变更为"*ST景峰"，证券代码仍为"000908"，股票日涨跌幅限制仍为5%。公司股票将于 2025年10月22日开市起停牌一天，自2025年10月23日开市起复牌。 ST景峰于2014年12月上市，主营业务产品涵盖了心脑血管、肿瘤、骨科、儿科、妇科等重大疾病领 域。由于公司经营不善，加之细分市场竞争激烈，ST景峰2023年末经审计净资产为负值，公司经营所 需流动性发生困难，缺乏必要的生产经营现金，导致"16景峰01"债券逾期，公司股票曾被实施退市风险 警示。 今年6月16日开市起公司被撤销退市风险警示及部分其他风险警示并继续被实施其他风险警示，公司股 票简称由"*ST景峰"变更为"ST景峰"。ST景峰最 ...

谢建军对飞鱼影像的技术实力、专业服务理念及创新规划给予高度认可，尤其赞赏周新玲积极顺应行业趋势、主动探索服务新模式的前瞻思路。他强 调："资源共享、优势互补是促进会与会员单位实现共同发展的核心驱动力。"谢建军表示，促进会将充分发挥"桥梁纽带"作用，为飞鱼影像等优质会员单 位搭建更多跨行业交流、项目对接的合作平台；同时他提议双方结合自身优势，在联合策划医疗健康科普讲座、企业员工定制化健康筛查等特色活动基础 上，进一步融入公益元素，通过开展关爱弱势群体的公益行动，持续拓展合作领域、丰富合作形式，让服务既惠及企业会员，也传递社会温暖。 10月20日下午，湖南省企业文化促进会常务理事单位——长沙飞鱼医学影像诊断中心有限公司（以下简称"飞鱼影像"）董事长周新玲、总经理刘志会 一 行，专程到访湖南省企业文化促进会（以下简称"促进会"）。促进会执行会长、长沙市湘潭商会会长谢建军出席座谈，促进会联合工会主席、执行秘书长 颜润林热情接待。双方围绕资源共享、特色活动共创、会员服务升级等议题深入交流，旨在打通医疗健康与企业文化建设的合作链路，探索互利共赢新路 径。 座谈伊始，颜润林简要介绍了促进会近期工作成效。他表示，飞鱼影像作为 ...

Group 1 - As of August 22, 2025, Kunming Pharmaceutical Group's stock price is 14.39 yuan, down 0.07 yuan or 0.48% from the previous trading day [1] - The trading volume on that day was 233,900 hands, with a transaction amount of 335 million yuan and a turnover rate of 3.09%, resulting in a total market capitalization of 10.893 billion yuan [1] - Kunming Pharmaceutical Group operates in the traditional Chinese medicine sector of the pharmaceutical manufacturing industry, focusing on drug research, production, and sales, with products covering cardiovascular, anti-malarial, and anti-tumor fields [1] Group 2 - The latest semi-annual report indicates that Kunming Pharmaceutical Group received increased holdings from several long-term funds in the second quarter, including the National Social Security Fund, the Monetary Authority of Macao, and the Kuwait Investment Authority, which became top ten circulating shareholders [1] - The National Social Security Fund holds 10.292 million shares, the Monetary Authority of Macao holds 8.7643 million shares, and the Kuwait Investment Authority holds 5.659 million shares, while Central Huijin holds 11.815 million shares [1] - On August 22, 2025, the net outflow of main funds from Kunming Pharmaceutical Group was 12.4156 million yuan, accounting for 0.11% of the circulating market value, with a cumulative net outflow of 105 million yuan over the past five trading days, representing 0.96% of the circulating market value [1]

Company Overview - Chengyi Pharmaceutical reported a closing price of 15.98 yuan on August 11, down 0.63 yuan, representing a decline of 3.79% from the previous trading day [1] - The stock reached a high of 16.69 yuan and a low of 15.70 yuan during the trading session, with a total trading volume of 563,700 hands and a transaction amount of 900 million yuan [1] Financial Performance - On August 11, the net inflow of main funds was 50.85 million yuan, accounting for 0.97% of the circulating market value [1] - Over the past five trading days, there was a cumulative net outflow of 29.42 million yuan, which is 0.56% of the circulating market value [1] Industry Position - Chengyi Pharmaceutical is focused on the chemical pharmaceutical sector, headquartered in Zhejiang Province [1] - The company's product range includes treatments for infections, cardiovascular diseases, and digestive system disorders, with a research pipeline that features multiple innovative drugs and generic products [1]

Group 1 - The core viewpoint of the news highlights the recent stock performance of Yuheng Pharmaceutical, which saw an increase of 8.01% on July 31, reaching a price of 3.91 yuan per share with a trading volume of 8.85 billion yuan and a turnover rate of 11.38%, resulting in a total market capitalization of 87.81 billion yuan [1] - Yuheng Pharmaceutical, based in Harbin, Heilongjiang Province, is a modern pharmaceutical company that integrates research, production, and sales, initially focusing on orthopedic treatments and expanding into cardiovascular and other therapeutic areas, establishing a product cluster that includes cardiovascular, musculoskeletal, and nutritional medications [1] - The company emphasizes strict quality management and international innovation, having established production bases and marketing systems that comply with GMP and GSP standards, while actively developing CMO platforms and chronic disease services, aiming to become a leading pharmaceutical enterprise in China with an international perspective [1] Group 2 - As of May 30, Yuheng Pharmaceutical had 107,100 shareholders, with an average of 19,600 circulating shares per shareholder [2] - For the first quarter of 2025, Yuheng Pharmaceutical reported a revenue of 551 million yuan, a year-on-year decrease of 7.06%, while the net profit attributable to shareholders was 60.25 million yuan, reflecting a year-on-year increase of 15.24% [2]